Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcopenia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid 1Heart Failure 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1Anemia, Aplastic 1

Interventions

Glutamine 2sagopilone 1nicotinamide-beta-riboside 1allantoicase 1Vitamin D 1Vitamin B 6 1Vitamin B 12 1Taxoids 1Tadalafil 1Sirolimus 1Prednisolone 1Paclitaxel 1Minocycline 1Metformin 1Losartan 1Hydroxychloroquine 1G(M1) Ganglioside 1Fatty Acids, Omega-3 1Exercise 1Everolimus 1Etoricoxib 1Ethosuximide 1Epoetin Alfa 1Dietary Supplements 1Dexamethasone 1Cryotherapy 1Bortezomib 1BID protein, human 1Acupuncture Therapy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × nicotinamide-beta-riboside × Clear all
NCT04112641 2025-07-30

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

University of Iowa

Phase 2 Active not recruiting
48 enrolled

Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡